Avidity Biosciences, Inc.
https://www.aviditybiosciences.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Avidity Biosciences, Inc.
Examining The Antibody-Drug Conjugate Pipeline
An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs. The earlier stage pipeline boasts a range of mechanistic approaches.
Avidity Is The Mid-Cap Rising Star Of 2024 So Far
New modalities and potential best-in-class challengers have excited investors in 2024 to date, but companies whose drugs have underperformed on the market have been punished.
The Prospects For Earlier-Stage Antibody-Drug Conjugates
Around 25 ADCs are in active Phase I/II trials, with a range of mechanistic approaches.
Big Pharma Leads Development Of Novel Antibody-Drug Conjugates
An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
-
Large Molecule
- Antibodies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice